JAK3 and ovarian carcinoma: Examining compounds that target two of the most common ovarian cancer aneuploidies concurrently (4q and 17p), Pf-06651600/ritlecitinib was identified as a potentially effective therapeutic, which disrupts the JAK3-STAT pathway (Figure 6).